Helicase Venture

Managing Partner and Co-founder Richard Tsai leads investment decisions, drawing on his position within the Tsai family that controls Taiwan's Fubon Group. Director John Lee, who also chairs medical distributor Hi-Clearance Inc., and Partner Joy Lee round out the core investment committee. The presence of two generations of the Lee family alongside Tsai suggests a collaborative but concentrated decision-making structure.

Helicase sources through its membership in the Biotechnology Innovation Organization (BIO) investor network, which provides access to vetted therapeutic and life-science startups emerging from US research hubs. Its Boston location at 1 Beacon Street places it within direct reach of Harvard and MIT spinouts. The firm's relationship with Hi-Clearance Inc. also creates a reverse-sourcing channel: Asian medical distributors identify unmet clinical needs that inform US scouting priorities.

Helicase functions as a hybrid — an asset manager with venture-capital form but family-office capital. The wealth behind the firm ties to the Tsai family's Fubon Group fortune, and it does not appear to raise third-party funds. Its co-investment structures, including Witty Mate Co. and direct board overlaps with J&V Energy Technology, resemble the operating-company relationships typical of single-family offices rather than independent VCs.

Hi-Clearance Inc. is a Taiwanese medical distribution company chaired by John Lee, who also serves as Director at Helicase. The two entities share leadership and strategic alignment: Helicase's early-stage investments in therapeutics and devices gain a potential commercial partner in Hi-Clearance, which distributes medical products throughout Taiwan's hospital systems. This creates an integrated pipeline from US FDA approval to Asian market access.

Helicase concentrates on healthcare services and digital health, with additional exposure to industrial technology and the energy transition. Its strategy emphasizes early-stage companies that can benefit from cross-border scaling between US innovation centers and Asian commercial networks. The firm does not publicly disclose explicit sector exclusions, but its portfolio and affiliated operations center on regulated industries where distribution partnerships create durable advantages.

Available evidence points to a direct-investment model, consistent with family-linked vehicles that prefer balance-sheet deals over fund commitments. The firm's structural ties to Hi-Clearance and J&V Energy Technology suggest it takes board seats or observer rights alongside equity positions. There is no public record of Helicase acting as a limited partner in third-party venture funds.

The capital originates from the Tsai family, founders of Taiwan's Fubon Financial Holding — one of the island's largest financial-services conglomerates with interests spanning banking, insurance, and securities. Richard Tsai's role as Managing Partner and Co-founder represents the family's direct venture-investment activity in North America, distinct from Fubon's institutional investment operations.